Literature DB >> 19031938

Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions.

M J Gaspar1, J De Miguel, J D García Díaz, M Díez.   

Abstract

BACKGROUND: The aim of the present study was to evaluate the diagnostic value of the tumour markers carcinoembryonic antigen (CEA), carbohydrate antigens CA 125, CA 15.3, CA 19.9 and tumor-associated glycoprotein 72 (TAG 72) in the pleural fluid (PF) of patients with pleural effusions of different etiologies. PATIENTS AND METHODS: One hundred and fifty-five patients with pleural effusions (40 malignant, 84 benign and 31 paraneoplastic) were studied prospectively. The concentration of the tumour markers in serum and PF were measured by magnetic particle enzyme immunoassay. The PF to serum (PF/S) concentration ratios were calculated.
RESULTS: The concentrations of CEA, CA 15.3, CA 19.9 and TAG 72 in PF and the PF/serum ratios were significantly higher in effusions of malignant and paraneoplastic origin than in those of benign origin. The receiver operating characteristic (ROC) curves were calculated for each marker and the diagnostic cut-off point was selected as the value that offered a specificity of 100% (CEA: 6.5 ng/ml; CA 15.3:62.4 IU/l; TAG 72:10.9 IU/l). CEA presented the greatest sensitivity [45% in the malignant group, 38.7% in the paraneoplastic group, and 41.4% in the pooled group (combined malignant and paraneoplastic)]. TAG 72 presented the largest area under the curve (0.89 in the malignant group and 0.80 in the pooled group). The diagnostic efficacy of the PF/S ratios was not better than measurement of the tumour markers in pleural fluid. The highest diagnostic accuracy for the diagnosis of malignant pleural effusions was achieved by grouping the markers in a panel comprising CEA, CA 15.3 and TAG 72; this showed a sensitivity of 75% and a negative predictive value of 79.1% . In the subgroup of patients with negative cytology, the sensitivity was 41.2% for CEA, 35.5% for CA 15.3 and 33.3% for TAG 72. The combination of these three markers achieved a sensitivity of 84.6%.
CONCLUSION: The combined measurement of CEA, CA 15.3 and TAG 72 in pleural fluid is a useful complementary test in the differential diagnosis of pleural effusions of malignant origin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19031938

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  14 in total

1.  Pleural fluid tumour markers in malignant pleural effusion with inconclusive cytologic results.

Authors:  L Antonangelo; R K Sales; A P Corá; M M P Acencio; L R Teixeira; F S Vargas
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

2.  Elevated survivin is associated with a poor response to chemotherapy and reduced survival in lung cancer with malignant pleural effusions.

Authors:  Do-Sim Park; Ki-Eun Hwang; Hyeok Shim; Byoung-Ryun Kim; Keum-Ha Choi; Seong-Hoon Park; Seok-Don Park; Eun-Taik Jeong; Hak-Ryul Kim
Journal:  Clin Exp Metastasis       Date:  2011-11-02       Impact factor: 5.150

3.  Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusion.

Authors:  Mohamed Y Elsammak; Adel Attia; Hoda A Hassan; Taysser M Zaytoun; Mahmoud Shorman; Moosa Suleman
Journal:  Tumour Biol       Date:  2012-06-09

Review 4.  Management of malignant pleural effusion.

Authors:  Jack A Kastelik
Journal:  Lung       Date:  2013-01-13       Impact factor: 2.584

5.  Diagnostic Significance of CA15-3 with Combination of HER-2/neu Values at 85th Percentiles in Breast Cancer.

Authors:  Karuvaje Thriveni; Vijayalaxmi Deshmane; Girija Ramaswamy; Lakshmi Krishnamoorthy
Journal:  Indian J Clin Biochem       Date:  2012-12-11

6.  Combining clinical and analytical parameters improves prediction of malignant pleural effusion.

Authors:  Luis Valdés; Esther San-José; Lucía Ferreiro; Francisco-Javier González-Barcala; Antonio Golpe; José M Álvarez-Dobaño; María E Toubes; Nuria Rodríguez-Núñez; Carlos Rábade; Adriana Lama; Francisco Gude
Journal:  Lung       Date:  2013-10-02       Impact factor: 2.584

7.  Diagnostic Value of Six Tumor Markers for Malignant Pleural Effusion in 1,230 Patients: A Single-Center Retrospective Study.

Authors:  Xin Fan; Yanqing Liu; Zhigang Liang; Shanshan Wang; Jing Yang; Aihua Wu
Journal:  Pathol Oncol Res       Date:  2022-04-20       Impact factor: 2.874

8.  Clinical diagnostic utility of CA 15-3 for the diagnosis of malignant pleural effusion: A meta-analysis.

Authors:  Qiang Wu; Min Li; Shu Zhang; Lu Chen; Xingting Gu; Feng Xu
Journal:  Exp Ther Med       Date:  2014-10-30       Impact factor: 2.447

9.  Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer.

Authors:  Ying Swan Ho; Lian Yee Yip; Nurhidayah Basri; Vivian Su Hui Chong; Chin Chye Teo; Eddy Tan; Kah Ling Lim; Gek San Tan; Xulei Yang; Si Yong Yeo; Mariko Si Yue Koh; Anantham Devanand; Angela Takano; Eng Huat Tan; Daniel Shao Weng Tan; Tony Kiat Hon Lim
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

10.  Fucosylated Glycans in α1-Acid Glycoprotein for Monitoring Treatment Outcomes and Prognosis of Cancer Patients.

Authors:  Shin Yazawa; Ryo Takahashi; Takehiko Yokobori; Rie Sano; Akira Mogi; Abby R Saniabadi; Hiroyuki Kuwano; Takayuki Asao
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.